Novavax does not have a forecast for U.S. orders in 2022: CEO Erck - Yahoo Finance

Novavax missed Wall Street expectations but remains optimistic about the fourth quarter and 2023.

Novavax (NVAX) missed Wall Street expectations Monday after its second quarter earnings showed softer-than-expected demand in global vaccine sales, forcing the company to slash its 2022 outlook by 50… [+2849 chars]

full article...